Merkel cell carcinoma-derived macrophage migration inhibitory factor (MIF) may promote persistence of Chronic
Gabriel F Alencar1,2, Haroldo J Rodriguez1,3,4,5, Thomas H Pulliam4
1Beirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.
Abstract:
While concurrent diagnoses of Merkel cell carcinoma (MCC) and other cancers, like Chronic lymphocytic leukemia (CLL), are rare, patients with MCC have a 30-fold higher incidence of CLL. While these increases have been attributed to the ability of CLL to suppress immune responses allowing for the emergence of MCC, here we found evidence that MCC could support the persistence of CLL. Using single cell sequencing approaches and computational analyses of MCC and CLL from a patient where both cancers were present in the same lymph node, we found that production of macrophage migration inhibitory factor (MIF) by MCC could promote the persistence of CLL through stimulation of CD74 and CXCR4. These results may explain why blood cell counts rapidly normalized after treatment for MCC and were maintained at normal levels despite the absence of treatment for CLL.
